Advances in genetics: widening our understanding of prostate cancer.

Prostate cancer is a leading cause of cancer-related death in Western men. Our understanding of the genetic alterations associated with disease predisposition, development, progression, and therapy response is rapidly improving, at least in part, owing to the development of next-generation sequencing technologies. Large advances have been made in our understanding of the genetics of prostate cancer through the application of whole-exome sequencing, and this review summarises recent advances in this field and discusses how exome sequencing could be used clinically to promote personalised medicine for prostate cancer patients.

F1000Research. 2016 Jun 27*** epublish ***

Angela C Pine, Flavia F Fioretti, Greg N Brooke, Charlotte L Bevan

Molecular Oncology, School of Biological Sciences, University of Essex, Colchester, Essex, UK., Androgen Signalling Laboratory, Division of Cancer, Department of Surgery and Cancer, Imperial Centre for Translational & Experimental Medicine, Imperial College London, London, UK., Molecular Oncology, School of Biological Sciences, University of Essex, Colchester, Essex, UK; Androgen Signalling Laboratory, Division of Cancer, Department of Surgery and Cancer, Imperial Centre for Translational & Experimental Medicine, Imperial College London, London, UK., Androgen Signalling Laboratory, Division of Cancer, Department of Surgery and Cancer, Imperial Centre for Translational & Experimental Medicine, Imperial College London, London, UK.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe